US0311621009 - Common Stock

We assign a fundamental rating of **6** out of 10 to **AMGN**. **AMGN** was compared to 609 industry peers in the **Biotechnology** industry. **AMGN** scores excellent on profitability, but there are some minor concerns on its financial health. **AMGN** has a correct valuation and a medium growth rate. **AMGN** also has an excellent dividend rating. This makes **AMGN** very considerable for dividend investing!

In the past year **AMGN** was profitable.

In the past year **AMGN** had a positive cash flow from operations.

Each year in the past 5 years **AMGN** has been profitable.

Each year in the past 5 years **AMGN** had a positive operating cash flow.

The **Return On Assets** of **AMGN** (**8.36%**) is better than **96.83%** of its industry peers.

Looking at the **Return On Equity**, with a value of **98.82%**, **AMGN** belongs to the top of the industry, outperforming **99.67%** of the companies in the same industry.

The 3 year average ROIC (**16.82%**) for **AMGN** is well above the current ROIC(**10.97%**). The reason for the recent decline needs to be investigated.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 8.36% | ||

ROE | 98.82% | ||

ROIC | 10.97% |

ROA(3y)10.41%

ROA(5y)11.4%

ROE(3y)114.71%

ROE(5y)98.47%

ROIC(3y)16.82%

ROIC(5y)17.33%

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 33.95% | ||

PM (TTM) | 28.2% | ||

GM | 73.74% |

OM growth 3Y-2.56%

OM growth 5Y-3.18%

PM growth 3Y-9.49%

PM growth 5Y23.51%

GM growth 3Y-2.39%

GM growth 5Y-1.64%

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), **AMGN** is creating some value.

Compared to 1 year ago, **AMGN** has a worse debt to assets ratio.

Looking at the **Altman-Z score**, with a value of **1.70**, **AMGN** is in the better half of the industry, outperforming **68.33%** of the companies in the same industry.

The Debt to FCF ratio of **AMGN** is **6.45**, which is on the high side as it means it would take **AMGN**, **6.45** years of fcf income to pay off all of its debts.

With a **Debt to Equity ratio** value of **7.71**, **AMGN** is not doing good in the industry: **87.00%** of the companies in the same industry are doing better.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 7.71 | ||

Debt/FCF | 6.45 | ||

Altman-Z | 1.7 |

ROIC/WACC1.02

WACC10.73%

With a **Current ratio** value of **2.86**, **AMGN** is not doing good in the industry: **70.67%** of the companies in the same industry are doing better.

The **Quick ratio** of **AMGN** (**2.56**) is worse than **72.33%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 2.86 | ||

Quick Ratio | 2.56 |

Measured over the past 5 years, **AMGN** shows a small growth in **Earnings Per Share**. The EPS has been growing by **7.06%** on average per year.

The **Revenue** has been growing slightly by **1.91%** in the past year.

Measured over the past years, **AMGN** shows a small growth in **Revenue**. The Revenue has been growing by **2.87%** on average per year.

EPS 1Y (TTM)0.39%

EPS 3Y6.05%

EPS 5Y7.06%

EPS growth Q2Q5.53%

Revenue 1Y (TTM)1.91%

Revenue growth 3Y4.06%

Revenue growth 5Y2.87%

Revenue growth Q2Q3.77%

EPS Next Y7.09%

EPS Next 2Y7.23%

EPS Next 3Y7.05%

EPS Next 5Y5.11%

Revenue Next Year7.2%

Revenue Next 2Y11.28%

Revenue Next 3Y8.42%

Revenue Next 5Y5.31%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

Compared to the rest of the industry, the **Price/Earnings** ratio of **AMGN** indicates a rather cheap valuation: **AMGN** is cheaper than 97.50% of the companies listed in the same industry.

The **Price/Forward Earnings** ratio is **13.23**, which indicates a correct valuation of **AMGN**.

Based on the **Price/Forward Earnings** ratio, **AMGN** is valued cheaper than 97.50% of the companies in the same industry.

When comparing the **Price/Forward Earnings** ratio of **AMGN** to the average of the S&P500 Index (**20.22**), we can say **AMGN** is valued slightly cheaper.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 14.93 | ||

Fwd PE | 13.23 |

96.17% of the companies in the same industry are more expensive than **AMGN**, based on the **Enterprise Value to EBITDA** ratio.

Based on the **Price/Free Cash Flow** ratio, **AMGN** is valued cheaper than 97.50% of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 15.36 | ||

EV/EBITDA | 13.35 |

The high **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.

PEG (NY)2.11

PEG (5Y)2.12

EPS Next 2Y7.23%

EPS Next 3Y7.05%

Compared to an average industry **Dividend Yield** of **33.94**, **AMGN** pays a better dividend. On top of this **AMGN** pays more dividend than 98.33% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3.14% |

The dividend of **AMGN** is nicely growing with an annual growth rate of **10.76%**!

Dividend Growth(5Y)10.76%

Div Incr Years12

Div Non Decr Years12

DP58.9%

EPS Next 2Y7.23%

EPS Next 3Y7.05%

**AMGEN INC**

NASDAQ:AMGN (12/8/2023, 7:00:01 PM)

After market: 269.12 0 (0%)**269.12**

**-2.19 (-0.81%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap144.03B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3.14% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 14.93 | ||

Fwd PE | 13.23 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)2.11

PEG (5Y)2.12

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 8.36% | ||

ROE | 98.82% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 33.95% | ||

PM (TTM) | 28.2% | ||

GM | 73.74% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.3

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 7.71 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 2.86 | ||

Quick Ratio | 2.56 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)0.39%

EPS 3Y6.05%

EPS 5Y

EPS growth Q2Q

EPS Next Y7.09%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)1.91%

Revenue growth 3Y4.06%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y